UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes

Cell reports. Medicine, 2021-09, Vol.2 (9), p.100387-100387, Article 100387

2021

Volltextzugriff (PDF)

Body Composition Is the Main Determinant for the Difference in Type 2 Diabetes Pathophysiology Between Japanese and Caucasians

Diabetes care, 2014-03, Vol.37 (3), p.796-804

2014

Volltextzugriff (PDF)

Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes

Diabetes, obesity & metabolism, 2018-09, Vol.20 (9), p.2238-2245

2018

Volltextzugriff (PDF)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population

Journal of diabetes investigation, 2022-04, Vol.13 (4), p.652-656

2022

Volltextzugriff (PDF)

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

Clinical pharmacokinetics, 2016-06, Vol.55 (6), p.657-672

2016

Volltextzugriff (PDF)

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

Clinical pharmacokinetics, 2016-06, Vol.55 (6), p.657-672

2016

Volltextzugriff (PDF)

Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials

Clinical pharmacokinetics, 2021-10, Vol.60 (10), p.1335-1348

2021

Volltextzugriff (PDF)

Ethnic Differences in Insulin Sensitivity, β-Cell Function, and Hepatic Extraction Between Japanese and Caucasians: A Minimal Model Analysis

The journal of clinical endocrinology and metabolism, 2014-11, Vol.99 (11), p.4273-4280

2014

Volltextzugriff (PDF)

Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus

Clinical pharmacokinetics, 2016-11, Vol.55 (11), p.1457-1463

2016

Volltextzugriff (PDF)

Population Pharmacokinetics of Semaglutide for Type 2 Diabetes

Diabetes therapy, 2019-04, Vol.10 (2), p.649-662

2019

Volltextzugriff (PDF)

Impact of demographics and disease progression on the relationship between glucose and HbA1c

European journal of pharmaceutical sciences, 2017-06, Vol.104, p.417-423

2017

Volltextzugriff (PDF)

Population Pharmacokinetics of Liraglutide, a Once-Daily Human Glucagon-Like Peptide-1 Analog, in Healthy Volunteers and Subjects With Type 2 Diabetes, and Comparison to Twice-Daily Exenatide

Journal of clinical pharmacology, 2010-08, Vol.50 (8), p.886-894

2010

Volltextzugriff (PDF)

Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment

Journal of clinical pharmacology, 2012-12, Vol.52 (12), p.1815-1823

2012

Volltextzugriff (PDF)

Modeling of 24-hour glucose and insulin profiles in patients with type 2 diabetes mellitus treated with biphasic insulin aspart

Journal of clinical pharmacology, 2014-07, Vol.54 (7), p.809-817

2014

Volltextzugriff (PDF)

Mathematical Modelling of Glucose‐Dependent Insulinotropic Polypeptide and Glucagon‐like Peptide‐1 following Ingestion of Glucose

Basic & clinical pharmacology & toxicology, 2017-10, Vol.121 (4), p.290-297

2017

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin

Journal of pharmacokinetics and pharmacodynamics, 2003-06, Vol.30 (3), p.221-235

2003

Volltextzugriff (PDF)

Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test

Journal of pharmacokinetics and pharmacodynamics, 2011-12, Vol.38 (6), p.713-725

2011

Volltextzugriff (PDF)

Predictive performance for population models using stochastic differential equations applied on data from an oral glucose tolerance test

Journal of pharmacokinetics and pharmacodynamics, 2010-02, Vol.37 (1), p.85-98

2010

Volltextzugriff (PDF)

Pharmacodynamic model of interleukin-21 effects on red blood cells in cynomolgus monkeys

Journal of pharmacokinetics and pharmacodynamics, 2007-08, Vol.34 (4), p.559-574

2007

Volltextzugriff (PDF)

Safety and Pharmacokinetics of ReN1869: A First Human Dose Study in Healthy Subjects after Single-Dose Administration

Journal of clinical pharmacology, 2003-01, Vol.43 (1), p.66-73

2003

Volltextzugriff (PDF)

Population pharmacokinetics of tiagabine in epileptic patients on monotherapy

European journal of pharmaceutical sciences, 2000-09, Vol.11 (3), p.247-254

2000

Volltextzugriff (PDF)

The Effects of a GLP‐1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model

CPT: pharmacometrics and systems pharmacology, 2015-01, Vol.4 (1), p.28-36

2015

Volltextzugriff (PDF)

ADOPT (A Dynamic HbA(1c) EndpOint Prediction Tool): A framework for Predicting Primary Endpoint in Phase 3 Diabetes Trials

Journal of pharmacokinetics and pharmacodynamics, 2013, Vol.40, p.S57

2013

Volltextzugriff (PDF)

Comparison of sandwich enzyme-linked immunoadsorbent assay and radioimmunoassay for determination of exogenous glucagon-like peptide-1(7–36)amide in plasma

Journal of pharmaceutical and biomedical analysis, 1995-06, Vol.13 (7), p.841-850

1995

Volltextzugriff (PDF)

Non-linear mixed effects modeling of sparse concentration data from rats: application to a glycogen phosphorylase inhibitor

European journal of drug metabolism and pharmacokinetics, 2002-07, Vol.27 (3), p.203-212

2002

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Life Sciences & Biomedicine
(27)
Humans
(23)
Pharmacology & Pharmacy
(21)
Male
(14)
Diabetes
(11)
Adult
(10)
Female
(10)
Biological And Medical Sciences
(9)
Diabetes Mellitus, Type 2 - Blood
(9)
Medical Sciences
(9)
Middle Aged
(9)
Diabetes Mellitus, Type 2 - Drug Therapy
(8)
Dose-Response Relationship, Drug
(6)
Hypoglycemic Agents - Pharmacokinetics
(6)
Hypoglycemic Agents - Therapeutic Use
(6)
Pharmacology. Drug Treatments
(6)
Aged
(5)
Endocrinology & Metabolism
(5)
Glucose
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes

Body Composition Is the Main Determinant for the Difference in Type 2 Diabetes Pathophysiology Between Japanese and Caucasians

Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials

Ethnic Differences in Insulin Sensitivity, β-Cell Function, and Hepatic Extraction Between Japanese and Caucasians: A Minimal Model Analysis

Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus

Population Pharmacokinetics of Semaglutide for Type 2 Diabetes

Impact of demographics and disease progression on the relationship between glucose and HbA1c

Population Pharmacokinetics of Liraglutide, a Once-Daily Human Glucagon-Like Peptide-1 Analog, in Healthy Volunteers and Subjects With Type 2 Diabetes, and Comparison to Twice-Daily Exenatide

Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment

Modeling of 24-hour glucose and insulin profiles in patients with type 2 diabetes mellitus treated with biphasic insulin aspart

Mathematical Modelling of Glucose‐Dependent Insulinotropic Polypeptide and Glucagon‐like Peptide‐1 following Ingestion of Glucose

Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin

Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test

Predictive performance for population models using stochastic differential equations applied on data from an oral glucose tolerance test

Pharmacodynamic model of interleukin-21 effects on red blood cells in cynomolgus monkeys

Safety and Pharmacokinetics of ReN1869: A First Human Dose Study in Healthy Subjects after Single-Dose Administration

Population pharmacokinetics of tiagabine in epileptic patients on monotherapy

The Effects of a GLP‐1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model

ADOPT (A Dynamic HbA(1c) EndpOint Prediction Tool): A framework for Predicting Primary Endpoint in Phase 3 Diabetes Trials

Comparison of sandwich enzyme-linked immunoadsorbent assay and radioimmunoassay for determination of exogenous glucagon-like peptide-1(7–36)amide in plasma

Non-linear mixed effects modeling of sparse concentration data from rats: application to a glycogen phosphorylase inhibitor

Suchergebnisse filtern